Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medivive vs Omada Health

Medivive
Graded #343

Higher grade

vs+3.799999999999997
Omada Health
Graded #436

Lower grade

The verdict

Medivive takes it — 59.4/100 to 55.6/100.

Medivive grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medivive is a US telehealth service offering compounded semaglutide and tirzepatide for weight loss, filled through a licensed pharmacy, with providers licensed in all 50 states and no insurance required.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedivive +25
70
45
Dose & formulationEven
40
40
Clinical oversightOmada Health +14
63
77
Labs & monitoringMedivive +3
64
61
FulfillmentOmada Health +1
61
62
Contract termsEven
55
55
Medivive · left barOmada Health · right bar

The numbers

MetricMediviveOmada Health
WeighScore59.4/10055.6/100
GradeCC
Scorecard rank#343#436
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Medivive

Graded #343 · C

Strengths

  • Compounded semaglutide and tirzepatide with providers licensed in all 50 states
  • No insurance required; one-stop for GLP-1 plus TRT, NAD+ and longevity care
  • Medication filled through a licensed pharmacy

Where it loses points

  • Monthly pricing not published; disclosed only after an AI intake
  • No legal entity or named pharmacy disclosed
  • Service states are not individually listed
Omada Health

Graded #436 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard